Skip to content

Advertisement

European Journal of Medical Research

Open Access

The impact of insulin pump therapy to oxidative stress in patients with diabetic nephropathy

  • Xing-Guang Zhang1,
  • Yan-Qi Zhang2,
  • Qian-Peng Cheng1,
  • Yi Cao1,
  • Jian-Min Sun1 and
  • Xiao-Feng Lv1Email author
European Journal of Medical Research201823:7

https://doi.org/10.1186/s40001-018-0304-2

Received: 5 June 2017

Accepted: 29 January 2018

Published: 12 February 2018

Abstract

Background

The oxidative stress resulting from increased production of ROS plays a crucial role in the development of diabetic complications. We aim to explore the relationships between oxidative stress, diabetic nephropathy (DN) and short-term insulin pump intensive therapy (insulin therapy).

Methods

Levels of 8-hydroxy-deoxyguanosine (8-OHdG), 3-nitrotyrosine (3-NT), glutathione (GSH), superoxide dismutase (SOD) and Interleukin-6 (IL-6) were estimated before and after 2 weeks of insulin therapy in normal group (NC) and type 2 diabetic (DM) with normal albuminuria (NA), microalbuminuria (MA) and clinical albuminuria (CA).

Results

In DM group, levels of 8-OHdG and 3-NT were higher than those in NC group (P < 0.05); GSH and SOD were lower (P < 0.05). And their levels changed with urine albumin–creatinine ratio (P < 0.05). After insulin therapy, these derangements were significantly ameliorated and the changes in NA and MA groups were more significant than CA group (P < 0.05). Correlation analysis showed glycated hemoglobin, the course of disease, the HOME-IR and fasting plasma glucose were positively correlated with 8-OHdG and 3-NT, but negatively correlated with GSH and SOD.

Conclusions

The oxidative stress gradually increased with the magnitude of DN, and insulin pump intensive therapy can significantly ameliorate the derangements in the early stage of DN.

Trial registration NCT03174821

Keywords

Diabetic nephropathyOxidative stressInsulin pump intensive therapy

Background

Type 2 diabetes mellitus (T2DM) is a multifactorial and genetically heterogeneous disease which is characterized by insulin hypo-secretion and/or insulin resistance (IR). The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 [1]. About 30% of type 1 diabetes mellitus (T1DM) and 20–50% of T2DM patients suffered DN, which account for one-third of all dialysis and renal allograft sufferers [2]. Nephropathy is the major cause of disability and death among people suffering diabetes mellitus. However, the molecular mechanisms responsible for its development are, as yet, incompletely understood.

The recent study [3] suggested that oxidative stress resulting from increased production of ROS plays a crucial role in the development of diabetic complications. Oxidative stress is recently recognized as a major factor of cellular damages caused by hyperglycemia [4]. Some studies [5, 6] also have demonstrated that oxidative stress is correlated to the average blood glucose concentration within 24 h and glycosylated hemoglobin (HbAlc). These carbonyl compounds form covalent adducts with specific lysine and arginine residues in proteins and intracellular advanced glycation end products (AGEs), which consequently alter protein function. Several large randomized controlled trials have conclusively demonstrated that early strict glycemic control can significantly decrease the risk of DN but increase the risk of the accidence of hypoglycemia [7, 8]. Insulin pump therapy is better than subcutaneous injection in terms of the drug safety and effectiveness. Furthermore, it can effectively avoid the insulin resistance and increase the sensitivity by human insulin preparations [9].

Above all, in order to understand the effect of oxidative stress on diabetic nephropathy and to further precede the clinical valid treatment measures, we monitored the level of oxidative stress of patient in different stages of diabetic nephropathy before and after insulin pump therapy.

Patients and methods

Subjects

A total of 80 type 2 diabetes patients and 80 non-diabetic age- and gender-matched subjects were randomly collected between October 2010 and June 2012 from the military general hospital of Beijing. Diagnosis of diabetes was made according to the criteria of the World Health Organization by Endocrinology Department of the military general hospital of Beijing (patients were excluded if they had received a diagnosis of type 1 diabetes). Male to female ratio was 7:9. Mean age was 54.1 ± 7.4 years (range 40–70). The study was carried out in compliance with the Institutional Ethics Committee and informed consent being given to each participant. The inclusion criterion and exclusion criterion are described in Table 1.
Table 1

The inclusion and exclusion criteria of this study subjects

Inclusion criterion

Fasting plasma glucose (FPG) ≥ 10 mmol/l and/or 2-h plasma glucose (2hPG) ≥ 15 mmol/l

Exclusion criterion

(1) Using antioxidant drugs within 1 month

(2) Accompanied with acute and chronic severe complications, fever, malignant tumor, nephritis, and congestive heart failure

(3) Accompanied with diabetic ketosis, ketoacidosis, severe hypoglycemia, and hyperosmolar hyperglycemic state

(4) With other endocrine diseases, autoimmune diseases or connective tissue diseases

(5) Having history of infection within 1 month

(6) Having drug or alcohol dependence

(7) Severe hypoxia and stress state (e.g., cardiovascular events, trauma, surgery, and consumptive disease)

DN status was determined by measurements of urinary albumin-to-creatinine ratio (UACR). The 80 T2DM patients were divided into three sub-groups: normal albuminuria (NA), microalbuminuria (MA) and clinical albuminuria (CA) and then were given 2-week insulin pump therapy. 80 healthy persons were randomly chosen as normal group (NC), male to female ratio was 31:49 and mean age 53.1 ± 7.0 years (Table 2).
Table 2

The group were divided by UACR

Groups

UACR (mg/g)

Total

Normal albuminuria (NA) (n = 35)

UACR < 30

n = 80

Microalbuminuria (MA) (n = 30)

30 ≤ UACR < 300

Clinical albuminuria (CA) (n = 15)

UACR ≥ 300

Normal group (NC) (n = 80)

Non-diabetic subjects

n = 80

Pre-therapy detection

All patients underwent the physical examination, which included height (cm), weight (kg), blood pressure (mmHg) and body mass index (BMI, kg/m2). Venous blood samples were drawn from all subjects in the fasting at least 8 h. (1) The fasting plasma glucose were measured by means of glucose oxidase method (Glucose GOD FS, DiaSys Diagnostic Systems GmbH, Germany). (2) Determination of hepatic and renal function, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and HbAlc was performed with automatic biochemistry analyzer (HITACHI 7020, Japanese), at the same time determining the blood C-reactive protein (CRP). (3) Fasting serum insulin (FINS) was determined by immunoluminometric assay detected by BECKMANCOULTER-ACCESS, American, and then the homeostasis model assessment-insulin resistance (HOMA-IR) was calculated by the formula: HOMA-IR = FINS × FPG/22.5. 5. The hepatic duct extracted 5 ml venous blood, precipitated, centrifuged and took the serum in the − 70 °C refrigerator to detect the level of the 3-NT, 8-OHdG, SOD, GSH (Elisa kit, Shanghai Jiang Lai Biological Technology Co. China) and IL-6 (PD6050, R&D Systems) by enzyme-linked immune competition assay.

First morning mid-stream clean urine (5 ml) was sent to endocrinology laboratory and the determination of urine albumin/creatinine (A/C) was measured by immune turbidimetry. 2-h plasma glucose (2hPG) was detected by standardized steamed bread meal test.

Insulin pump therapy

Initial dose calculation: the total requisite amount = 0.44 × weight (kg). The preprandial and basal amount, respectively, took up to 50% of integral dose. 15 min before meal, the preprandial insulin was equally given by three times. The basal insulin was pumped at 00:00–3:00, 3:00–8:00, 8:00–14:00, 14:00–20:00 and 20:00–24:00. The dosage of insulin given at 00:00–3:00 was the least to avoid the hypoglycemia, and the dosage at 3:00–8:00 was the maximum to deal with diabetes mellitus dawn phenomenon (about 150–200% of dosage at period of 00:00–3:00). Others were between these. The rapid blood glucose was measured at 3:00, 6:00, 9:30, 11:00, 14:00, 16:30, 19:00 and 21:00. If there was glycopenia in the patient, we would measure and record another blood sugar. The bolus and basal rates work to keep blood sugars constantly in control (FPG: 4–6 mmol/l, 2hPG: 5–8 mmol/l). After 2 weeks, all patients finished insulin pump therapy; the blood sugar, insulin and other biochemical indexes were tested next morning. The rest blood serum was kept in the − 70 °C refrigerator and the level of 3-NT, 8-OHdG, SOD, GSH and IL-6 was measured by enzyme-linked immune-sorbent assay. In the whole treatment period, all the subjects insist on the dietary therapy and physical exercise treatment, but without any oral hypoglycemic agents.

Statistical analysis

Statistical analyses were performed using software of SPSS 17.0. The measurement data were expressed as the mean ± SD. The results of before and after treatment with insulin pump were applied comparative t test to perform statistical analysis. The inter-group comparison was performed by one-way analysis of variance (ANOVA) methodology. The enumeration data were statistically analyzed by Chi square test. The correlation analysis between two factors was undertaken with simple linear correlation analysis. P < 0.05 was considered significant.

Results

Baseline parameters

Baseline parameters of all the participants in this study are presented in Table 3. There were no significant differences at baseline in terms of age, gender and diastolic blood pressure (DBP). The level of BMI, FPG, 2hPG, HbA1c, TG, TC, LDL-C, 8-OHdG, 3-NT, CRP, SBP and IL-6 in DM group was higher than that in NC group, and the level of GSH, SOD and HDL-C was lower than NC group, both of the differences were significant (P < 0.05).
Table 3

Baseline characteristics of DM and NC groups

 

Groups

T value/χ2

P

NC

DM

Gender (M/F)

31/49

35/45

0.413

0.630

Age (years)

53.1 ± 7.0

54.1 ± 7.4

− 0.845

0.4

BMI (kg/m2)

23.8 ± 1.3

24.7 ± 2.0

− 3.465

0.001*

SBP (mmHg)

127.1 ± 9.1

132.3 ± 12.1

− 3.097

0.002*

DBP (mmHg)

77.2 ± 6.2

77.4 ± 5.4

− 0.284

0.777

HBA1c (%)

5.2 ± 0.4

10.6 ± 1.5

− 30.098

0.000*

FPG (mmol/l)

4.6 ± 0.6

12.4 ± 1.8

− 38.143

0.000*

2hPG (mmol/l)

5.7 ± 0.4

16.5 ± 1.2

− 76.735

0.000*

HOMA-IR

1.4 ± 0.3

3.3 ± 0.5

− 26.932

0.000*

IL-6 (pg/l)

94.7 ± 11.2

167.90 ± 15.46

− 34.292

0.000*

TC (mmol/l)

4.0 ± 0.7

5.0 ± 1.0

− 7.198

0.0008*

TG (mmol/l)

1.5 ± 0.2

2.8 ± 0.9

− 13.499

0.000*

LDL (mmol/l)

2.5 ± 0.3

3.3 ± 0.8

− 8.112

0.000*

HDL (mmol/l)

1.4 ± 0.3

1.1 ± 0.4

6.121

0.000*

3-NT (nmol/l)

78.6 ± 7.4

121.5 ± 9.9

− 31.13

0.000*

SOD (U/ml)

124.8 ± 17.6

102.6 ± 20.5

7.332

0.000*

8-OHdG (ng/ml)

6.9 ± 3.8

25.4 ± 4.4

− 28.471

0.000*

GSH (mg/l)

152.5 ± 18.9

134.3 ± 15.3

6.663

0.000*

CRP (mg/l)

2.6 ± 0.7

8.46 ± 1.79

− 27.477

0.000*

Chi square test, others were t test; * P < 0.05 compared with the normal control group

The parameters of DM groups after insulin therapy

It is notable that the patients’ blood pressure, FPG, 2hPG, TG, TC, LDL-C, 8-OHdG, 3-NT, CRP and IL-6 levels were significantly decreased in the DM group after 2-week insulin pump therapy as compared with the levels before treatment (P < 0.05). Also, the levels of GSH, SOD and HDL-C were increased after 2-week treatment and the difference was significant (P < 0.05). However, HbA1c had no statistically significant differences among the treatments (Table 4).
Table 4

The parameters of DM groups at the baseline and at end of insulin pump therapy

 

Treatment

T value

P value

Pre-

Pro-

SBP (mmHg)

132.3 ± 12.1

130.5 ± 11.5

− 4.413

0.336

DBP (mmHg)

77.4 ± 5.4

75.5 ± 5.8

− 4.905

0.033*

HBA1c (%)

10.6 ± 1.5

10.5 ± 1.5

− 1.85

0.068

FPG (mmol/l)

12.4 ± 1.8

7.3 ± 1.0

− 23.006

0.000*

2hPG (mmol/l)

16.5 ± 1.2

9.1 ± 1.1

− 40.791

0.000*

IR

3.3 ± 0.5

2.6 ± 0.4

− 16.508

0.000*

TC (mmol/l)

5.0 ± 1.0

3.4 ± 0.9

− 15.075

0.000*

TG (mmol/l)

2.8 ± 0.9

2.4 ± 0.9

− 4.22

0.000*

CRP (mg/l)

8.46 ± 1.79

6.00 ± 1.60

− 13.14

0.000*

IL-6 (pg/l)

167.90 ± 15.46

106.95 ± 17.80

− 43.08

0.000*

3-NT (nmol/l)

121.5 ± 9.9

114.6 ± 9.5

− 12.064

0.000*

SOD (U/ml)

102.6 ± 20.5

115.0 ± 18.3

19.31

0.000*

8-OHdG (ng/ml)

25.4 ± 4.4

21.3 ± 4.9

− 12.109

0.000*

GSH (mg/l)

134.3 ± 15.3

145.0 ± 14.0

14.946

0.000*

LDL (mmol/l)

3.3 ± 0.8

2.5 ± 0.6

− 7.943

0.000*

HDL (mmol/l)

1.1 ± 0.4

1.3 ± 0.4

4.881

0.000*

P < 0.05 between pre-treatment and pro-treatment in the DM group

Oxidative stress indicators and inflammatory factor levels among NC group and each DM sub-groups before insulin pump therapy

The levels of 8-OHdG, 3-NT, CRP and IL-6 were reduced in the group of NA, MA and CA compared with NC group (P < 0.05), whereas the GSH and SOD levels were significantly raised as shown in Fig. 1. However, the changes among NA, MA and CA groups were not statistically significant (P > 0.05, Table 5).
Fig. 1

The comparison of SOD (a), 3-NT (b), 8-OHdG (c), GSH (d), CRP (e) and IL-6 (f) levels among NC, NA, MA and CA groups before insulin pump therapy

Table 5

The parameters of NC group and each DM sub-groups at baseline of insulin pump therapy

Groups

3-NT (nmol/l)

SOD (U/ml)

8-OHdG (ng/ml)

GSH (mg/l)

CRP (mg/l)

IL-6 (pg/l)

NC

78.6 ± 7.4

124.8 ± 17.6

6.9 ± 3.8

152.5 ± 18.9

2.6 ± 0.7

94.7 ± 11.2

NA

119.6 ± 11.2*

104.9 ± 19.0*

24.5 ± 4.4*

136.3 ± 15.2*

8.29 ± 1.80*

165.67 ± 16.11*

MA

122.0 ± 8.4*

101.6 ± 20.9*

26.0 ± 3.9*

135.7 ± 13.4*

8.51 ± 1.85*

168.65 ± 15.69*

CA

124.8 ± 8.9*

99.0 ± 23.7*

26.6 ± 5.2*

126.8 ± 17.9*

8.76 ± 1.70*

171.63 ± 13.40*

P < 0.05 compared with NC group

Oxidative stress indicators in DM sub-groups before and after insulin pump therapy

After 2-week insulin pump intensive therapy, the levels of GSH (Fig. 2a) and SOD (Fig. 2b) levels were increased (P < 0.05); the levels of 8-OHdG (Fig. 2d) and 3-NT (Fig. 2c) were both lower than that pre-treatment. Furthermore, the differences in the NA and MA group were more significant than that in the CA group (P < 0.05) (Table 6).
Fig. 2

The comparison of the levels of GSH (a) and SOD (b), 3-NT (c) and 8-OHdG (d) in NA, MA and CA groups before and after insulin pump therapy

Table 6

The changes of oxidative stress indicators in DM sub-groups at the baseline and at end of insulin pump therapy

Groups

NA

MA

CA

F value

P value

3-NT (nmol/l)

 Pre-treatment

119.6 ± 11.2

122.0 ± 8.4

124.8 ± 8.9

  

 Pro-treatment

111.9 ± 9.2

114.5 ± 8.6

120.9 ± 9.8

  

 D value

− 7.6 ± 5.1*

− 7.5 ± 5.0*

− 3.9 ± 4.5

3.316

0.042*

SOD (U/ml)

 Pre-treatment

104.9 ± 19.0

101.7 ± 20.9

99.0 ± 23.7

  

 Pro-treatment

118.7 ± 17.8

114.3 ± 17.2

107.7 ± 20.4

  

 D value

13.7 ± 4.9*

12.7 ± 6.0*

8.6 ± 5.7

4.588

0.013*

8-OHdG (ng/ml)

 Pre-treatment

24.5 ± 4.4

26.0 ± 3.9

26.6 ± 5.2

  

 Pro-treatment

20.0 ± 4.0

21.4 ± 4.3

24.3 ± 6.4

  

 D value

− 4.5 ± 2.8*

− 4.6 ± 3.2*

− 2.3 ± 2.7

3.543

0.034*

GSH (mg/l)

 Pre-treatment

136.3 ± 15.2

135.7 ± 13.4

126.8 ± 17.9

  

 Pro-treatment

147.8 ± 13.1

147.2 ± 9.6

133.8 ± 18.0

  

 D value

11.5 ± 6.2*

11.5 ± 6.7*

7.0 ± 5.2

3.225

0.045*

P < 0.05 comparison with CA group

The relationship between oxidative stress indicators and other parameters

To determine the relationship between oxidative stress indicators and other parameters (glycated hemoglobin, the course of disease, the HOME-IR and fasting plasma glucose), we used Pearson relation assessment. We observed that the levels of 8-OHdG and 3-NT were positively correlated with the index of glycated hemoglobin, the course of disease, the HOME-IR and fasting plasma glucose (P < 0.05) (Figs. 3, 4; Table 7). As shown in Figs. 5 and 6, a negative association was observed between the levels of GSH and SOD and the index of glycated hemoglobin, the course of disease, the HOME-IR and fasting plasma glucose (the correlation index was − 0.382, − 0.343, − 0.428, − 0.450 for GSH and − 0.330, − 0.271, − 0.372, − 0.396 for SOD in turn, respectively, P < 0.05).
Fig. 3

The relation assessment between 8-OHdG and parameters such as glycated hemoglobin (a), fasting plasma glucose (b), the course of disease (c), and the HOME-IR (d)

Fig. 4

The relation assessment between 3-NT and parameters such as glycated hemoglobin (a), fasting plasma glucose (b),the course of disease (c), and the HOME-IR (d)

Table 7

The correlation coefficients of the 8-OHdG, 3-NT, GSH and SOD

 

8-OHdG

3-NT

SOD

GSH

r

P value

r

P value

r

P value

r

P value

GH

0.811

0.032

0.829

0.003

− 0.330

0.024

− 0.382

0.035

CD

0.264

0.015

0.298

0.007

− 0.271

0.015

− 0.343

0.026

HOME-IR

0.807

0.022

0.827

0.046

− 0.372

0.004

− 0.428

0.005

FPG

0.857

0.018

0.902

0.002

− 0.396

0.003

− 0.450

0.019

Fig. 5

The relation assessment between SOD and parameters such as glycated hemoglobin (a), fasting plasma glucose (b), the course of disease (c) and the HOME-IR (d)

Fig. 6

The relation assessment between GSH and parameters such as glycated hemoglobin (a), fasting plasma glucose (b), the course of disease (c), and the HOME-IR (d)

Discussions

DN is one of the most important microvascular complications of diabetes, including diabetic neuropathy and diabetic retinopathy [3, 10]. Oxidative stress resulting from an imbalance between antioxidants and oxidants lead to cell damage in the harmful irritant [11]. It is well known that the generation of mitochondrial reactive oxygen species (ROS) is the primary initiating event that subsequently activates other pathways implicated in the development of the complications of diabetes [12]. Hyperglycemia has been demonstrated to be the key contributor in the development of DN in both type 1 and type 2 diabetes [13]. On the other hand, persistent hyperglycemia damages cells by four major pathways on the decline of kidney function, namely the hexosamine and polyol pathways, protein kinase C isoforms, and formation of the reactive carbonyl compounds methylglyoxal (MG) and glyoxal [1416].

The recent study [17] has showed that 8-OHdG was significantly elevated in the diabetic and the pre-diabetic groups (including patients with impaired glucose tolerance (IGT) or elevated fasting glucose) compared with the normal people. And the change of 8-OHdG had an evident heredity [18]. The scientists (Ceriello et al. [27]) proved that with the high concentration of blood sugar, 3-NT was induced by the increased expression of ONOO–, H2O2, OH and NO, and lead to denatured protein and enzyme, DNA damage and cell apoptosis. GSH combined with glutathione reductive and vitamin C to form a benign circulation of antioxidant process [19]. And by catalyzing the superoxide anion radical to produce disproportionation reaction, SOD maintained the balance of ROS in vivo [20]. Another report [21] illustrated that the condition of high glucose and high fat in the T2DM induced the oxidative stress, and the excess of ROS/RNS also could decrease the level of GSH and SOD. Brownlee stated that as the byproduct of reaction of free radicals with DNA, protein and lipid 8-OHdG, 3-NT can reflect the level of oxygen free radical in the body so as the level of GSH and SOD to the damage of antioxidant system.

Our study found that the level of 8-OHdG and 3-NT in DM group was significantly higher than NC group, and GSH and SOD level is obviously lower than that in NC group. Both of the changes were related to the level of UACR. There is no difference between the antioxidant ability of NA, MA and CA groups, which showed that the enhanced oxidation ability rather than the antioxidant ability of weakening played the leading role in the enhancement of oxidative stress in DN patients. The results in Table 3 suggested that patients of type 2 diabetes mellitus had severe oxidative stress and the ROS became worse in development of DN. Correlation analysis showed that 8-OHdG and 3-NT had positive relation with glycated hemoglobin, the course of disease, the HOME-IR and fasting plasma glucose. The result suggested that abnormal glucose metabolism played an important role in the pathophysiology of DN.

Insulin pump can mimicry the pulsatile secretion of insulin under normal condition in vivo, and we used the INS-pump to properly release insulin in order to maintain the stability of blood sugar in the base and additional quantity. Large-scale clinical trials have confirmed that intensive insulin therapy can provide rapid and effective glycemic control, microcirculation and reduced substances harmful to the kidney, produced by the body in early type 2 diabetes mellitus patients, and thereby reducing the leakage of urine protein, slow the progression of DN [22]. Our study found that after short-term insulin pump therapy, the levels of 8-OHdG and 3-NT were significantly reduced but GSH and SOD were increased in MA, NA and CA groups. The changes were even significant in MA and NA groups than in CA group. These results indicated the critical functions of intensive insulin therapy in suppress oxidative stress.

Numerous studies [23] showed that elevated blood glucose can cause a large amount of ROS, protein glycosylation and glucose autoxidation, leading to the occurence of oxidative stress. Persistent high blood sugar can also activate protein kinase C/NAD(P)H oxidase pathway to increase production of ROS in vivo [24]. There was also research [25] that confirmed hyperglycemia by activation of protein kinase A (protein kinases A, PKA) resulting in decreased production of NADPH and levels of intracellular GSHt, leading to the decreased antioxidant capacity in kidney tissues. In this study, correlation analysis showed 8-OHdG and 3-NT were positively correlated with fasting plasma glucose. The insulin pump therapy can quickly hypoglycemic; we considered use of insulin pump therapy could improve patient oxidative stress through improving insulin resistance and smooth hypoglycemic. In addition, T2DM patients always combine with dyslipidemia characterized by increasing triglyceride (TG) levels and HDL-C decrease [26]. Along with the increasing TG, fatty acids (FFA) were elevated and underwent mitochondrial uncoupling and β oxidation to produce large amount of ROS causing direct damage to the body [27, 28]. The FFA could also destruct pancreatic β cells to reduce insulin secretion, which lead to hyperglycemia and caused body damage [29, 30]. Recent studies [31] showed that inflammation is also involved in the occurrence and development of DN. Persistent chronic hyperglycemia damaged renal cells, the damaged renal cells released inflammatory mediators, and then filtered off and caused leukocytes activation in the site of injury. Renal biopsy specimens in patients with diabetes and diabetic rats were found in the excessive increase of leukocyte adhesion molecules and macrophage infiltration. Leukocytes, granulocytes, monocytes, macrophages and other cells are involved in different inflammatory lesions of DN process [32].

Conclusions

After the insulin pump therapy, we observed that blood lipids in DM group (except HDL) decreased and inflammatory cytokines’, IL-6 and CRP, levels decreased. Therefore, we conclude that insulin pump therapy may improve the state of the patient’s body by lipid levels and inflammatory state thereby improving the body’s oxidative stress.

Therefore, we advocate to intensive insulin therapy in early DN, in order to obtain greater benefits.

Abbreviations

DN: 

diabetic nephropathy

8-OHdG: 

8-hydroxy-deoxyguanosine

3-NT: 

3-nitrotyrosine

GSH: 

glutathione

SOD: 

superoxide dismutase

IL-6: 

interleukin-6

NC: 

normal control

DM: 

diabetes

NA: 

normal albuminuria

MA: 

microalbuminuria

CA: 

clinical albuminuria

SOD: 

superoxide dismutase

UACR: 

urine albumin–creatinine ratio

Declarations

Authors’ contributions

XGZ and XFL defined the research theme. XGZ and YQZ collected the data. QPZ and YC analyzed the data. JMS interpreted the results. XFL worked on associated data collection and their interpretation. All authors read and approved the final manuscript.

Acknowledgements

None.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The authors ensure the authenticity and effectiveness of obtained data.

Consent for publication

The study was approved by the ethnic committee of PLA Army General Hospital. Consent form was obtained from all patients for data publication.

Ethics approval and consent to participate

Not applicable.

Funding

None.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Endocrinology, PLA Army General Hospital, Beijing, China
(2)
China National Institute of Standardization, Beijing, China

References

  1. Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(10):2568–9 (Epub 2004/09/29).View ArticlePubMedGoogle Scholar
  2. Chu YW, Lin HM, Wang JJ, Weng SF, Lin CC, Chien CC. Epidemiology and outcomes of hypoglycemia in patients with advanced diabetic kidney disease on dialysis: a national cohort study. PLoS ONE. 2017;12(3):e0174601. https://doi.org/10.1371/journal.pone.0174601 (Epub 2017/03/30).View ArticlePubMed CentralPubMedGoogle Scholar
  3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25 (Epub 2005/05/28).View ArticlePubMedGoogle Scholar
  4. Esposito K, Giugliano D. Hyperglycemia and vascular damage role of oxidative stress. Recent Prog Med. 2002;93(3):172–4 (Epub 2002/04/11).Google Scholar
  5. Mehrotra S, Ling KL, Bekele Y, Gerbino E, Earle KA. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with type 2 diabetes mellitus. Diabet Med. 2001;18(2):109–15 (Epub 2001/03/17).View ArticlePubMedGoogle Scholar
  6. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7. https://doi.org/10.1001/jama.295.14.1681 (Epub 2006/04/13).View ArticlePubMedGoogle Scholar
  7. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72. https://doi.org/10.1056/nejmoa0802987 (Epub 2008/06/10).View ArticlePubMedGoogle Scholar
  8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713–20 (Epub 1998/09/11).View ArticlePubMed CentralGoogle Scholar
  9. Corney SM, Dukatz T, Rosenblatt S, Harrison B, Murray R, Sakharova A, et al. Comparison of insulin pump therapy (continuous subcutaneous insulin infusion) to alternative methods for perioperative glycemic management in patients with planned postoperative admissions. J Diabetes Sci Technol. 2012;6(5):1003–15 (Epub 2012/10/16).View ArticlePubMed CentralPubMedGoogle Scholar
  10. Bloomgarden ZT. Diabetic retinopathy and diabetic neuropathy. Diabetes Care. 2007;30(3):760–5. https://doi.org/10.2337/dc07-zb03 (Epub 2007/03/01).View ArticlePubMedGoogle Scholar
  11. Ray SD, Lam TS, Rotollo JA, Phadke S, Patel C, Dontabhaktuni A, et al. Oxidative stress is the master operator of drug and chemically-induced programmed and unprogrammed cell death: implications of natural antioxidants in vivo. BioFactors. 2004;21(1–4):223–32 (Epub 2005/01/05).View ArticlePubMedGoogle Scholar
  12. Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal. 2007;9(3):343–53. https://doi.org/10.1089/ars.2007.9.ft-19 (Epub 2006/12/23).View ArticlePubMedGoogle Scholar
  13. Dave GS, Kalia K. Hyperglycemia induced oxidative stress in type-1 and type-2 diabetic patients with and without nephropathy. Cell Mol Biol (Noisy-le-grand). 2007;53(5):68–78 (Epub 2007/06/05).Google Scholar
  14. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70. https://doi.org/10.1161/circresaha.110.223545.View ArticlePubMed CentralGoogle Scholar
  15. Queisser MA, Yao D, Geisler S, Hammes HP, Lochnit G, Schleicher ED, et al. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes. 2010;59(3):670–8. https://doi.org/10.2337/db08-1565.View ArticleGoogle Scholar
  16. Neumiller JJ, Hirsch IB. Management of hyperglycemia in diabetic kidney disease. Diabetes Spectr. 2015;28(3):214–9. https://doi.org/10.2337/diaspect.28.3.214.View ArticlePubMed CentralGoogle Scholar
  17. Al-Aubaidy HA, Jelinek HF. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur J Endocrinol. 2011;164(6):899–904. https://doi.org/10.1530/eje-11-0053 (Epub 2011/03/26).View ArticlePubMedGoogle Scholar
  18. Zengi A, Ercan G, Caglayan O, Tamsel S, Karadeniz M, Simsir I, et al. Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 2011;119(8):467–71. https://doi.org/10.1055/s-0031-1275289 (Epub 2011/04/08).View ArticlePubMedGoogle Scholar
  19. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol. 2002;64(5–6):1019–26 (Epub 2002/09/06).View ArticlePubMedGoogle Scholar
  20. Dincer Y, Alademir Z, Ilkova H, Akcay T. Susceptibility of glutatione and glutathione-related antioxidant activity to hydrogen peroxide in patients with type 2 diabetes: effect of glycemic control. Clin Biochem. 2002;35(4):297–301 (Epub 2002/07/24).View ArticlePubMedGoogle Scholar
  21. Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, et al. Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. Mediators inflamm. 2015;2015:105828. https://doi.org/10.1155/2015/105828 (Epub 2015/12/23)View ArticlePubMed CentralPubMedGoogle Scholar
  22. Li GW. Early intensive insulin therapy in newly diagnosed type 2 diabetes: the size of the problem. Zhonghua Nei Ke Za Zhi. 2010;49(1):1–2 (Epub 2010/04/02).PubMedGoogle Scholar
  23. Adaikalakoteswari A, Rema M, Mohan V, Balasubramanyam M. Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with type 2 diabetes and microangiopathy. Int J Biochem Cell Biol. 2007;39(9):1673–84. https://doi.org/10.1016/j.biocel.2007.04.013 (Epub 2007/06/02).View ArticlePubMedGoogle Scholar
  24. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339(2):69–75. https://doi.org/10.1056/nejm199807093390202 (Epub 1998/07/09).View ArticlePubMedGoogle Scholar
  25. Xu Y, Osborne BW, Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol. 2005;289(5):F1040–7. https://doi.org/10.1152/ajprenal.00076.2005 (Epub 2005/06/16).View ArticlePubMedGoogle Scholar
  26. Sorensen SV, Frick KD, Wade A, Simko R, Burge R. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Clin Ther. 2009;31(4):862–79. https://doi.org/10.1016/j.clinthera.2009.04.015 (Epub 2009/05/19).View ArticlePubMedGoogle Scholar
  27. Schonfeld P, Wojtczak L. Brown adipose tissue mitochondria oxidizing fatty acids generate high levels of reactive oxygen species irrespective of the uncoupling protein-1 activity state. Biochim Biophys Acta. 2012;1817(3):410–8. https://doi.org/10.1016/j.bbabio.2011.12.009 (Epub 2012/01/10).View ArticlePubMedGoogle Scholar
  28. Barazzoni R, Zanetti M, Gortan Cappellari G, Semolic A, Boschelle M, Codarin E, et al. Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-kappaB inhibitor (IkappaB)-nuclear factor-kappaB (NFkappaB) activation in rat muscle, in the absence of mitochondrial dysfunction. Diabetologia. 2012;55(3):773–82. https://doi.org/10.1007/s00125-011-2396-x (Epub 2011/12/14).View ArticlePubMedGoogle Scholar
  29. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia. 2003;46(10):1297–312. https://doi.org/10.1007/s00125-003-1207-4 (Epub 2003/09/19).View ArticlePubMedGoogle Scholar
  30. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29(3):351–66. https://doi.org/10.1210/er.2007-0023 (Epub 2007/12/01).View ArticlePubMedGoogle Scholar
  31. Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C, et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg. 2007;17(11):1464–74 (Epub 2008/01/26).View ArticlePubMedGoogle Scholar
  32. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia. 2007;50(2):471–80. https://doi.org/10.1007/s00125-006-0497-8 (Epub 2006/12/13).View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement